Bavarian Nordic passed up a potential multi billion dollar treatment for low $ potential retroviral vector technology and poxvirus based delivery platform?? Ya ok. Bavarian Nordic knew NovaCaps now (CIAB) was garbage and wouldn't make it so like a real biotech they cut their losses and went on treatments that had potential.
Again common sense.
"The preclinical study, commissioned by Bavarian Nordic, used “targeted chemotherapy” to treat malignant ascites just as PharmaCyte biotech does. In the study, words like “complete tumor remission” and “cure” were used to describe the results, so why didn’t Bavarian Nordic continue on with its work?
Well, at the time of the study, Bavarian Nordic, the forerunner to Austrianova, had three in-house technologies: (i) the encapsulation technology; (ii) a retroviral vector technology; and (iii) a poxvirus based delivery platform. As a result of the attacks of 9/11 in the United States, Bavarian Nordic decided to focus strategically on the development of a smallpox vaccine based on its poxvirus platform and chose to divest the other two technologies, which eventually were moved into Austrianova."
News 
Market Data 
Discover 
